In summary, the major apparent hurdle is that therapies targeting the SphK/S1P rheostat in cancer patients (for cancer therapy) may prove to be a double-edged sword where predisposing conditions such as obesity and diabetes are also presented. This evidence concerns the gene MBTPS1 and diabetes mellitus.